TL;DR
Turn your wind-down time into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A USC Schaeffer Center model estimates that donanemab could generate $138,300 in lifetime societal value per person when started two years earlier than the timing in a pivotal clinical trial, 32% above the modeled value at trial timing. The estimate includes health and economic benefits but excludes the drug, screening and monitoring costs; the duration of treatment benefits remains uncertain.
A new USC Schaeffer Center model estimates that starting the Alzheimer’s drug donanemab two years earlier could raise its lifetime societal value by 32%, to $138,300 per person, compared with treatment timing based on a pivotal clinical trial. Published Oct. 7 in Alzheimer’s & Dementia, the analysis projects benefits for patients, care partners and public programs, but does not subtract the cost of the drug or the screening and monitoring needed to provide it.
The researchers modeled three scenarios for people similar to participants in a Phase 3 trial: receiving donanemab at the trial’s treatment timing, starting it two years earlier while still after symptoms usually emerge, or receiving no treatment. For both treatment scenarios, the model applied a 29% slowing of disease progression, matching the trial result compared with placebo after 18 months. The lifetime estimates are projections, not measurements of outcomes over patients’ entire lives.
At trial timing, the model projected that treated people would live about 0.3 years longer than those receiving no treatment, with one fewer year in severe dementia. It also estimated gains of 0.37 disability-free years and 0.63 years living in the community. The resulting $104,900 lifetime value per person included $52,300 in health-related quality-of-life gains, $23,800 in reduced unpaid caregiving and $22,200 in medical-cost offsets, largely accruing to Medicaid. The model estimated Medicaid costs would fall by about $1,640 per person annually, or 13%.
With treatment started two years sooner, the estimated value rose to $138,300 per person. A scenario incorporating potentially greater treatment effects, which the report says emerging evidence may support, raised the estimate to $179,400. By contrast, when researchers assumed benefits lasted only four years rather than for the rest of a person’s life, the value at trial timing fell to $49,100; earlier treatment was estimated at $56,400, 15% higher. These figures describe modeled health and economic value, not savings guaranteed to patients or government budgets.
Earlier Diagnosis Could Change Treatment Value
The findings speak to a practical issue in Alzheimer’s care: treatment may have more value when offered earlier, but people can wait years between symptoms and diagnosis. The report says diagnosis occurs, on average, 3.5 years after symptoms first appear. Better identification could give eligible patients and clinicians more opportunity to consider treatment before disease progression advances further.
The estimates also frame potential benefits beyond the person taking the drug. Reduced time with severe dementia could mean less unpaid caregiving, while modeled medical-cost offsets largely fall to Medicaid. Those effects may matter to families and public programs as the U.S. dementia burden grows. The model, however, does not show that earlier treatment will produce these results for every patient, and its value estimates do not establish that treatment is cost-effective once all delivery costs are included.
Alzheimer's disease early detection kit
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
How Researchers Built the Estimates
The team used a dynamic microsimulation model developed through the Schaeffer Center’s U.S. Cost of Dementia Project, a federally funded effort to quantify dementia’s costs. Researchers drew on national health surveys and studies of dementia progression to project cognitive status and lifetime outcomes. The modeled group was designed to resemble participants in donanemab’s pivotal Phase 3 trial.
The report places the work against an estimated $818 billion U.S. cost for Alzheimer’s and related dementias in 2026, with the burden expected to grow as the population ages. It also points to FDA-approved blood-based biomarker tests introduced in the past year and newer digital cognitive assessments as possible ways to identify disease earlier. The researchers did not model those tools’ costs as part of the reported treatment-value estimates.
The study also explored hypothetical future medicines. A treatment slowing progression by 50% was assigned a lifetime societal value of $208,700 to $276,700, depending on when it began. A hypothetical treatment that halted progression was estimated at $530,000 to $648,300. These are scenarios, not results from available medicines; the report notes more than 150 drugs are in clinical testing.
“Our research suggests that investments in early detection could help ensure that patients start treatments when they’re more likely to provide the greatest benefit to patients and society.”
— Jack Chapel, lead author, USC Schaeffer scholar and assistant research professor at the USC Price School of Public Policy
As an affiliate, we earn on qualifying purchases.
Treatment Duration and Costs Remain Open
The estimates depend on assumptions about how much donanemab slows disease progression and how long that effect lasts. The report says the drugs are new and the duration of benefit is uncertain; its four-year-benefit scenario produced substantially lower values than the scenario assuming effects lasted for a patient’s lifetime. The size of any additional benefit from starting earlier is also uncertain, since the higher $179,400 estimate relies on potentially stronger effects suggested by emerging evidence.
The analysis excludes drug, screening and monitoring costs, so it does not establish the net economic return of expanding access. It also does not show how the modeled averages translate to individual patients or resolve which patients would be eligible, how quickly diagnosis could be improved, or how coverage and delivery barriers might change. The estimates should be read as projections under stated assumptions, not as promises of longer life or reduced costs.
As an affiliate, we earn on qualifying purchases.
Evidence and Access Will Shape Decisions
The study is published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association. The next evidence needed includes longer follow-up on how durable treatment effects are, as well as research on the costs and practical demands of diagnosing, screening and monitoring patients earlier. Those details would help determine whether the modeled gains can be achieved in routine care.
For health systems and policymakers, the report points toward weighing early-detection investment against the full costs of treatment and delivery. The modeling does not announce a change to clinical guidance or coverage policy. Decisions about whether and when to use a treatment remain separate from the study’s societal-value estimates.
As an affiliate, we earn on qualifying purchases.
Key Questions
What did the study estimate about earlier donanemab treatment?
The model estimated $138,300 in lifetime societal value per person when treatment began two years earlier than the trial-based timing, 32% above the $104,900 estimate at trial timing. These are projections, not observed lifetime outcomes.
What does “societal value” include in the model?
It combines modeled health-related quality-of-life gains, reduced unpaid caregiving and medical-cost offsets. The researchers estimated the trial-timing value at $104,900 per person, with about half attributed to quality of life. The measure is not the same as a guaranteed financial saving.
Did the estimate include the cost of donanemab?
No. The reported value estimates exclude the drug’s cost as well as screening and monitoring costs. The study therefore does not establish the treatment’s net value after those expenses.
How certain are the projected benefits?
They depend on assumptions about treatment effects and duration. When the model limited the effect to four years, estimated value fell to $49,100 at trial timing and $56,400 with earlier treatment. The authors say how long benefits last remains uncertain.
Does the study change treatment or coverage recommendations?
No change to clinical guidance or coverage policy is reported. The paper provides modeled estimates that may inform future discussions; it does not itself establish who should receive treatment or whether access should be expanded.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
